Cancer research in Lebanon: Scope of the most recent publications of an academic institution (Review)
- Authors:
- Published online on: June 3, 2024 https://doi.org/10.3892/ol.2024.14484
- Article Number: 350
-
Copyright: © Tawil et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Cancer poses an important global public health challenge and ranks as the second leading cause of death worldwide, following heart diseases. The American Association of Cancer Research states that the primary objective of the study of cancer is the development of safe and effective approaches for the prevention, detection, diagnosis, treatment and cure of this disease (1). Advancing the understanding of cancer, including its treatment options, preventive measures and psychological impact, is crucial for making substantial progress in the reduction of its profound human and economic toll on the well-being of patients. Enormous sums of money have been spent on cancer research worldwide (2). However, due to extensive exposure to numerous environmental chemicals in everyday life and the complex nature of chemical mixtures (3), it is challenging for long-term safety evaluations to provide perpetual true results concerning cancer diagnosis and treatment as well as accurate updates. An ultimate cure for cancer remains the top aim of numerous researchers (4). Despite the marked increase in cancer research and the substantial growth in the number of cancer survivors over the past three decades, it is undeniable that the global occurrence of this disease continues to rise (5). Regarding cancer survival, it has been reported that during the last decade half of the individuals diagnosed with cancer in England survived their disease for ≥10 years (6). While there have been numerous advancements in the pharmacological treatments of tumors, and new highly sensitive techniques for the early diagnosis of pathologies, including imaging, laboratory tests, tumor biopsy, endoscopic examination, surgery, genetic testing and microfluidic systems have been developed (7,8), a definite cure for cancer remains elusive. Nevertheless, researchers persist in their efforts to develop new and more effective treatments and preventive measures for cancer. For example, long-term epidemiological studies have identified specific risk factors, such as the maintenance of a healthy weight, avoidance of tobacco, limitation of alcohol intake and protection of the skin that, if reduced, can prevent the development of certain types of cancers (9,10). Moreover, cancer risk prediction models based on these epidemiologic data have identified the risk of an individual carrying a genetic mutation for a specific cancer, such as BRCA 1 and/or BRCA 2 (11). Additionally, several innovative treatments, including hormonal therapy, monoclonal antibodies and chimeric antigen receptor T-cell therapy (12), are already being used alongside more traditional cancer therapies. Research efforts are now particularly focused on the role of gene editing and nanoparticles in combating cancer cells (13). Furthermore, a recent breakthrough in our understanding of the regulatory functions of small RNAs, originally discovered in plants, is providing new insights into the biology of cancer (14). Despite the clear rational and contemporary interest in cancer research, its assessment comes with challenges. Firstly, despite the recent surge in interest, there remains a lack of knowledge regarding the most effective methods for conducting research assessments (15). Secondly, in 2020, updates on the diagnosis and treatment of cancer were negatively impacted by the coronavirus disease (COVID)-19 pandemic. Restrictive measures and the closure of healthcare settings during the pandemic led to limited access to care, resulting in delays to cancer diagnosis, treatment and research updates regarding cancer incidence and etiologies (16). In Lebanon, particularly at the Lebanese American University (LAU), several scientific studies were conducted to explore new cancer therapies and preventive measures (17–20). However, according to a 2021 report from the Global Cancer Observatory of the National Cancer Registry, there were 11,589 new cancer cases and 6,438 cancer-related deaths in Lebanon in 2020 (21). One notable finding is the absence of data on the survival rate of cancer cases in the official Lebanese registry maintained by the Lebanese Ministry of Public Health (22).
Hence, the objectives of the present review are to examine cancer research methodologies documented in LAU libraries, with a particular focus on publications following the outbreak of COVID-19, assess these methodologies, consolidate their key findings and provide recommendations for future assessments. The present study encompasses various aspects of cancer research, including fundamental laboratory investigations and human studies, as well as basic scientific and applied research. It encompasses research pertaining to pediatric or adult cancer, as well as studies spanning the nursing, medical and public health aspects of cancer research. Consequently, the study seeks to achieve the following: i) Identify existing literature reviews that document approaches to the assessment of research impact and summarize these approaches; ii) summarize the findings of each study based on different cancer types; and iii) make recommendations to steer future cancer research towards addressing the specific requirements of the Lebanese population.
Study retrieval
The present study focused on the analysis of publications from the LAU (Beirut, Lebanon) over the past 5 years, specifically from 2017 to 2022. These publications were selected as a representative sample of a Middle Eastern academic and medical research center. During this time period, the School of Pharmacy and the School of Medicine at LAU actively participated in cancer research, conducted studies and stayed up-to-date with the latest advancements. The dataset used for analysis was obtained from SciVal (https://librairies.lau.edu.lb/research/databases/?index=S#id_libdbform), a research performance assessment tool that facilitates the analysis of data from Scopus and Web of Science (WOS). While there were variations in coverage between these two indices, the present study considered articles that appeared in both to provide a broader perspective on the correlation between citation count and author number. The study of published cancer research at LAU is based on the collaborative efforts between academic researchers and medical physicians. The search was initiated under ‘all subject areas’ and then proceeded using specific themes such as ‘medicine’ and ‘cancer research’. Published works were also extracted with specific keywords such as ‘neo*’, ‘tumor’, ‘cancer’, ‘oncol*’, ‘leukem*’, ‘lymph*’, ‘chemo*’ and ‘radio*’ as individual topics. The search in the category ‘institutions and groups’ was limited to ‘The Lebanese American University’; Lebanon was the country of choice in the category ‘countries/regions’ and the date limits were ‘2017–2022’. The data obtained from SciVal included i) article title, ii) author names, iii) author count, iv) citation count, v) field-weighted citation impact, and vi) CiteScore (CS). Bibliometric analysis was performed to compare the published works in the present study. In order to achieve this objective, the CS was used as the primary method for counting citations (23,24). The present review only included published articles and focused exclusively on peer-reviewed journals, even though the selection of journals may vary depending on the citation-based metric system being considered, resulting in different quartiles. No restrictions were made regarding author names and collaborations. Additionally, single- and hyper-authored publications, abstracts only, studies written in a language other than English, corrections to previous studies, errata, conference proceedings and book series were excluded.
Nearly all the published research from the specified years were included in the present study. To ensure accuracy and relevance, two independent reviewers conducted a thorough screening of all records based on the topic search. The screening process involved reviewing study titles for potential relevance to cancer research and examining the full-text articles for specific references to cancer.
Study design and setting
Between 2017 and 2022, a total of 2,137 research works by LAU were published in journals indexed in Scopus and WOS, covering various research fields. Out of these, 252 studies specifically focused on cancer research. Following the PRISMA guidelines, a thorough screening process was conducted based on the titles and abstracts of the publications as depicted in Fig. 1. After removing duplicates, corrections and errata, 124 papers remained for full-text review. Ultimately, 72 studies were deemed eligible and met the inclusion criteria. The number of publications gradually increased from 2017 until 2021, reaching its peak in 2020, when 26.3% of the studies were published and remained constant in 2021. However, the number of papers published dropped in 2022 (Fig. 2), comprising only 8.3% of the studies in this time period. Among the 72 publications, 25 focused on in vitro or animal studies, while 47 were patient-associated studies.
Considering the patient-associated studies, the highest proportion were literature reviews (18/72), followed by 5 systematic reviews, 1 meta-analysis and 22 observational studies of a cross-sectional, cohort or case-control nature. In addition, there was one interventional randomized controlled study. Fig. 3 provides an overview of the types of cancer studies reported by the LAU directory. Notably, two studies specifically targeted fetal cancer and metastasis, and involved pregnant women. Furthermore, five studies were conducted on the pediatric population.
Types of cancer and main endpoint
The faculty at LAU conducted research on various types of cancer. Some of these studies specifically investigated new herbal treatments and examined their anticancer properties (7/72 publications). In total, 28 of the 72 publications examined multiple cancer types or cancer in general. The primary objectives of these studies were twofold: Firstly, to explore pharmacological mechanisms and highlight pathways for cancer prevention (39.1%); and secondly, to evaluate the psychological challenges associated with cancer (30.4%). One study specifically focused on the identification of potential risk factors associated with cancer (5). The remaining studies each focused on specific types of cancer, such as lung, breast, colon or brain cancer. The main objectives of these studies were to investigate the incidence, prevalence, treatment options and prevention mechanisms for these specific types of cancer. Studies that focused on understanding the regulatory functions of small RNAs and human recombinant arginase I in the treatment of cancer constituted only 4.16% of all publications and were all published in 2020 (25–27). Additionally, several in vitro studies were conducted, which examined either a variety of cancer types or specific types of cancer. More comprehensive information on the various types of cancer researched is presented in Fig. 4.
Detailed description of LAU cancer studies
In the LAU dataset of 72 cancer publications, 38.89% covered all types of cancer, as indicated in Table I (18,28–53), while the remaining 61.11% focused on specific oncological types, as shown in Table II (10,17,19,20,25–27,54–90). These two tables provide additional information about each study, including its main focus, aim/purpose, study type, the type of cancer studied and key findings. Moreover, Figs. 5 and 6 depict the trends of cancer studies in terms of study types and types of cancer, respectively, across the years.
Table I.Publications on miscellaneous types of cancer according to study type and date of publication. |
Principal findings
The aim of the present investigation was to assess the quantity and quality of cancer studies reported by the LAU and explore their respective objectives and areas of focus. The review encompasses in vitro, in vivo and animal studies. A relatively high number of literature reviews and a prevalence of observational studies over experimental ones were conducted. This finding may be expected since observational studies are generally easier to perform, more convenient and less stringent compared with interventional studies, although they carry a lower level of evidence (91).
The aims of the included studies varied, and in some cases it appeared that the main objective was solely descriptive. Therefore, it is essential to conduct more interventional, experimental and well-controlled human studies that possess higher external validity and generalizability. Such studies would lead to more definitive conclusions and trustworthy recommendations (92).
The present analysis reveals that researchers at the LAU who are interested in cancer have focused on a variety of research areas. The most common type of study involved laboratory experiments, namely in vitro studies, which accounted for more than one-third of the LAU studies. Animal models are important tools in cancer research in vitro and in vivo, as they can be used in the identification of carcinogens, development of cancer therapies and drug screening, and for providing insights into the molecular mechanisms of tumor growth and metastasis (93). In addition, they are easy to manipulate, homogenous, accessible and do not require human participants (94). The latter point was highlighted in the present study, which showed that this type of study was most prevalent during 2020-2021, during the era of COVID-19.
Special updates and reviews on novel anticancer therapies were also shown to be prevalent in the present study. Notably, these findings, particularly those concerning the regulatory roles of small RNAs, have provided new insights to improve the global understanding of cancer biology. Although these types of studies were the most prevalent during the year 2020, prior to the spread of COVID-19 and the economic crisis that impacted research funding negatively in Lebanon, in coming years, broader revelations about fundamental aspects of cellular biology are likely to increase our understanding of the aberrant behavior of cancer cells and notably contribute to the advancement of biomedical research (14). In addition to anticancer treatment, other studies had additional objectives, such as determining the incidence and prevalence of specific types of cancer, identifying risk factors associated with certain cancers and exploring their socio-economic and psychological impacts. Indeed, the diverse range of findings from these studies on cancer underscores the broad spectrum of interest of researchers to this field and emphasizes the requirement for well-balanced, patient-centric research strategies that can yield improved outcomes and higher cure rates (95).
Just a few decades ago, clinical investigators and physicians were often advised to refrain from engaging in oncology due to its complexity and the discouraging clinical outcomes it yielded. Additionally, conducting cancer research required significant financial investment and relied on patients dedicating their time and effort (96). Currently, the primary challenge lies in the development of fundamental research on cancer prevention and treatment to impede the occurrence of new cases and reduce the global incidence of cancer.
Although the annual output of cancer research appears to be low when compared with that of other publications on different research subjects, a sharp increase in the number of cancer publications was noticed during the years of 2018 and 2019 in the present study. This underlines the increased involvement of LAU scholars in research as the aim of expanding the number of publications and citations, as well as the support offered by the academic institution as an incentive, seems to have had a positive impact on the publication rate of papers on cancer. In fact, Boutros and Fakih (97) argued in their recent publication that the number of academic publications was associated with academic promotion across all institutional settings. The authors also concluded that the positive consequences of the number of publications of each faculty member suggests that this factor should be a priority for administrators to consider when making decisions regarding promotion. LAU is a leading private and nonsectarian higher education institution that operates under a charter from the Board of Regents of the University of the State of New York, and has a large publication volume relative to its faculty size, which makes it an ideal source of relevant information (98). In terms of quality, LAU provides incentives for researchers to publish their studies in the top 10% of international journals; thus, LAU is a research-active institution of higher learning in Lebanon and the region, with no compromise in its commitment to quality teaching (99). Moreover, the urgency of conducting cancer research has escalated due to the high prevalence of cancer worldwide, with approximately one in two individuals receiving a cancer diagnosis in their lifetime (100). Despite current treatments, cancer-associated mortality and morbidity rates remain high (6). This global situation mirrors the situation in Lebanon, as indicated by the 2021 report from the Global Cancer Observatory of the National Cancer Registry, which revealed an increase in cancer cases despite ongoing research on cancer (22). As a result, oncological research has garnered public funding and global monetary investments to incentivize clinical investigators to pursue cancer research (101).
Despite the aforementioned increase in cancer-associated publications, a reduction in the number of publications was observed in 2021. A possible explanation for this is the outbreak of the novel COVID-19 that has impacted all types of research in various forms (102,103). Another potential explanation is the lack of funds required for research in general imposed by the severe socio-economic Lebanese crisis and political instability manifested by unprecedented rates of unemployment, inflation and poverty, and a rapid devaluation of the Lebanese currency since the beginning of 2021 (104,105).
Research on breast and colorectal cancer was found to be the most prevalent among that on all types of cancer, accounting for >30% of all cancer studies. This finding is not unexpected since, according to previous studies, these types of cancer were the most prevalent in Lebanon during the last 5 years (22,106). Unfortunately, research on breast and colorectal cancers decreased in 2022 since Lebanon was continuing to face a serious economic crisis with an effect on fiscal and human resources.
Reflecting upon the approaches to cancer research outlined in the present study, it is necessary to highlight several further recommendations. First, it is essential to conduct more research using real-life data in order to accurately assess the actual impact of research on cancer incidence, treatment, outcomes and prevention techniques. Additionally, there is a requirement for more clinical studies involving the users and beneficiaries of cancer research, such as patients and their families. It would be beneficial for these studies to involve a greater representation of individuals from real-world populations, with the development of a prospective study plan to establish specific targets for trial enrolment based on disease epidemiology and incidence. Moreover, it is crucial to allocate more robust, sustained and predictable funding for additional clinical and translational longitudinal molecular profiling studies in large and diverse cohorts of patients with cancer. This will aid in understanding the natural progression of cancers and exploring the role of biology and genetics in cancer health disparities. Furthermore, the national public health workforce should prioritize cancer control initiatives that aim to reduce the incidence, morbidity and mortality of cancer. These initiatives may also focus on improving the quality of life for individuals with cancer by implementing evidence-based interventions for prevention, early detection, diagnosis and treatment. Additionally, it is important to develop well-planned strategies to guide future cancer research.
Significance of the study and future implications for policy and practice
The issue of cancer research studies being underrepresented or misrepresented is an important factor contributing to therapy delays and proactive measures are required to address this. The importance of the present review lies in its summary of the different cancer studies that were conducted in an academic university during a 5-year period. The review has shown that cancer research is an attractive topic for many academic researchers; however, the spread of COVID-19 and the economic crisis had a major impact on this type of research, which might have contributed to a shift in study types towards more observational or in vitro studies as well as a remarkable reduction in research output, particularly after the spread of COVID-19 in 2020. From this perspective, it is essential to emphasize that researchers must re-focus their efforts on conducting studies associated with cancer, since cancer research should be recognized as one of the most prevalent health concerns, as is COVID-19. To develop new therapies, gain a deeper understanding of cancer prognosis and survivorship and ensure the availability of new drugs in all healthcare settings, a collaborative effort involving the diverse cancer research community in each country is necessary. Translational cancer research, particularly interventional or experimental human studies, is recommended to be an integral part of the delivery of oncology care, ensuring that valuable knowledge is gained in academic institutions and nationally. For this reason, policy proposals should be made to enhance access to digital healthcare, expand healthcare programs, allocate funds for experimental cancer research and provide financial support to healthcare institutions. Moreover, interventional studies that focus on anticancer therapy should be the primary interest of pharmaceutical companies as well as research centers since, according to the present results, only a few of these were conducted.
It is important to emphasize that the impact of cancer research can be amplified when organizations use a multidisciplinary approach, as demonstrated by the diversity of studies in the present review, which can guide and enhance future evaluations.
Conclusions
At present, scientists seldom contemplate an ultimate cure for cancer. However, further research on the short-term and long-term effects of current cancer therapies is necessary. For instance, efforts can be made to address the psychological and socioeconomic challenges faced by cancer patients during their treatment, or to find methods of mitigating the potential side effects experienced during therapy. By combining technological advancements with ongoing operational research, the field of oncology will be able to move on from the era when surgery and chemotherapy were the sole treatment options available.
Acknowledgements
The authors would like to thank Professor Samer Saab (Dean of Graduate Studies, Lebanese American University Beirut, Lebanon) for their final revision of the manuscript and valuable comments.
Funding
Funding: No funding was received.
Availability of data and materials
Not applicable.
Authors' contributions
NKS wrote the literature review, was responsible for the methodology and organized the findings. ST collected and analyzed data, designed and guided the study, and drafted and critically revised the final version of the manuscript. Data authentication is not applicable. Both authors have read and confirmed the final version of the manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
American Cancer Society, . The global economic cost of cancer. https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htmJune 10–2022 | |
American Association of Cancer Research, . Retrieved from. https://www.aacr.org/patients-caregivers/about-cancer/what-is-cancer-researchJune 10–2022 | |
Tsatsakis AM: Toxicological risk assessment and multi-system health impacts from exposure. Academic Press; 2021 | |
International Cancer Research Partnership, . Retrieved from. https:/www.icrpartnership.org/June 10–2022 | |
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI | |
Cancer Research UK, . Cancer risk statistics. 2019.https://www.cancerresearchuk.org/healt h-professional/cancer-statistics/riskMay 20–2022 | |
Taghizadehghalehjoughi A, Hacimuftuoglu A, Cetin M, Ugur AB, Galateanu B, Mezhuev Y, Okkay U, Taspinar N, Taspinar M, Uyanik A, et al: Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies. Nanomedicine (Lond). 13:1595–1606. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bargahi N, Ghasemali S, Jahandar-Lashaki S and Nazari A: Recent advances for cancer detection and treatment by microfluidic technology, review and update. Biol Proced Online. 24:52022. View Article : Google Scholar : PubMed/NCBI | |
Song C and Giovannucci E: Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol. 2:1154–1161. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chatila R, Mansour J, Mugharbil A, Nsouli G, O'Son L, Sayad E and Deeb ME: Epidemiology and survival of colorectal cancer in lebanon: A sub-national retrospective analysis. Cancer Control. 28:107327482110412212021. View Article : Google Scholar : PubMed/NCBI | |
Aaltonen L, Johns L, Järvinen H, Mecklin JP and Houlston R: Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res. 13:356–361. 2007. View Article : Google Scholar : PubMed/NCBI | |
Karlitepe A, Ozalp O and Avci CB: New approaches for cancer immunotherapy. Tumour Biol. 36:4075–4078. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, Kazi TA, Gupta R, Sinharoy S, Acharya K, et al: CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sci. 232:1166362019. View Article : Google Scholar : PubMed/NCBI | |
Weinstein IB and Case K: The history of cancer research: Introducing an AACR centennial series. Cancer Res. 68:6861–6862. 2008. View Article : Google Scholar : PubMed/NCBI | |
Richard S: BMJ blogs. Measuring research impact-all the rage but hard to get right. Godlee F: https://blogs.bmj.com/bmj/2018/07/30/richard-smith-measuring-research-impact-rage-hard-get-right/April 4–2023 | |
Yabroff KR, Wu XC, Negoita S, Stevens J, Coyle L, Zhao J, Mumphrey BJ, Jemal A and Ward KC: Association of the COVID-19 pandemic with patterns of statewide cancer services. J Natl Cancer Inst. 114:907–990. 2022. View Article : Google Scholar : PubMed/NCBI | |
El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J and Tabchy AB: Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: Perspectives and challenges. Hosp Pract (1995). 49:325–329. 2021. View Article : Google Scholar : PubMed/NCBI | |
Elias A, Shebaby WN, Nehme B, Faour W, Bassil BS, Hakim JE, Iskandar R, Dib-Jalbout N, Mroueh M, Daher C and Taleb RI: In vitro and in vivo evaluation of the anticancer and anti-inflammatory activities of 2-himachelen-7-ol isolated from Cedrus Libani. Sci Rep. 9:128552019. View Article : Google Scholar : PubMed/NCBI | |
Bahmad HF, Chalhoub RM, Harati H, Bou-Gharios J, Assi S, Ballout F, Monzer A, Msheik H, Araji T, Elajami MK, et al: Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β. Pharmacol Rep. 73:211–226. 2021. View Article : Google Scholar : PubMed/NCBI | |
Tfayli A, Al Assaad M, Fakhri G, Akel R, Atwi H, Ghanem H, El Karak F, Farhat F, Al Rabi K, Sfeir P, et al: Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. Cancer Med. 9:8406–8411. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians. 74:229–263. 2024.PubMed/NCBI | |
Republic of Lebanon Ministry of Public Health, . National Cancer Registry. https://moph.gov.lb/en/Pages/8/19526/national-cancer-registryMay 16–2022 | |
Baron S and Russell-Bennett R: Editorial: Beyond publish or perish: The importance of citations and how to get them. J Serv Mark. 30:257–260. 2016. View Article : Google Scholar | |
Jaafar R, Pereira V, Saab S and El-Kassar AN: Which journal ranking list? A case study in business and economics. EuroMed J Bus. 16:361–380. 2021. View Article : Google Scholar | |
Jayaraj R, Raymond G, Krishnan S, Tzou KS, Baxi S, Ram MR, Govind SK, Chandramoorthy HC, Abu-Khzam FN and Shaw P: Clinical theragnostic potential of diverse miRNA expressions in prostate cancer: A systematic review and meta-analysis. Cancers (Basel). 12:11992020. View Article : Google Scholar : PubMed/NCBI | |
Khalife H, Skafi N, Fayyad-Kazan M and Badran B: MicroRNAs in breast cancer: New maestros defining the melody. Cancer Genet. 246–247. 18–40. 2020.PubMed/NCBI | |
Elias-Rizk T, El Hajj J, Segal-Bendirdjian E and Hilal G: The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women. Sci Rep. 10:222282020. View Article : Google Scholar : PubMed/NCBI | |
Khazzaka A, Rassy E, Sleiman Z, Boussios S and Pavlidis N: Systematic review of fetal and placental metastases among pregnant patients with cancer. Cancer Treat Rev. 104:1023562022. View Article : Google Scholar : PubMed/NCBI | |
Atat OE, Farzaneh Z, Pourhamzeh M, Taki F, Abi-Habib R, Vosough M and El-Sibai M: 3D modeling in cancer studies. Hum Cell. 35:23–36. 2022. View Article : Google Scholar : PubMed/NCBI | |
Sacca L, Maroun V and Khoury M: Predictors of high trust and the role of confidence levels in seeking cancer-related information. Inform Health Soc Care. 47:53–61. 2022. View Article : Google Scholar : PubMed/NCBI | |
Karam L, Abou Staiteieh S, Chaaban R, Hayar B, Ismail B, Neipel F, Darwiche N and Abou Merhi R: Anticancer activities of parthenolide in primary effusion lymphoma preclinical models. Mol Carcinog. 60:567–581. 2021. View Article : Google Scholar : PubMed/NCBI | |
Hoteit M, Oneissi Z, Reda R, Wakim F, Zaidan A, Farran M, Abi-Khalil E and El-Sibai M: Cancer immunotherapy: A comprehensive appraisal of its modes of application. Oncol Lett. 22:6552021. View Article : Google Scholar : PubMed/NCBI | |
Jaafar W, Zaherddine V, Hussein F, Saliba NA and Hayeck N: Poor regulation implications in a low and middle income country based on PAH source apportionment and cancer risk assessment. Environ Sci Process Impacts. 23:1986–1996. 2021. View Article : Google Scholar : PubMed/NCBI | |
Chaftari P, Qdaisat A, Chaftari AM, Maamari J, Li Z, Lupu F, Raad I, Hachem R, Calin G and Yeung SJ: Prognostic value of procalcitonin, C-reactive protein, and lactate levels in emergency evaluation of cancer patients with suspected infection. Cancers (Basel). 13:40872021. View Article : Google Scholar : PubMed/NCBI | |
Massoud M, Ikdais W, Zeghondy J and Saad A: Provision of lifestyle recommendations to cancer patients: Results of a nationally representative survey of hematologists/oncologists. J Cancer Educ. 36:702–709. 2021. View Article : Google Scholar : PubMed/NCBI | |
Alrubai T, Khalil AM, Zaki R, Sinno L and Al Tabbah S: The psychological health of patients diagnosed with cancer in Iraq during the COVID-19 pandemic: A single center study. Psychooncology. 31:649–660. 2022. View Article : Google Scholar : PubMed/NCBI | |
Khaled K, Hundley V, Bassil M, Bazzi M and Tsofliou F: Validation of the European prospective investigation into cancer (EPIC) FFQ for use among adults in Lebanon. Public Health Nutr. 24:4007–4016. 2021. View Article : Google Scholar : PubMed/NCBI | |
Al-Koussa H, El Mais N, Maalouf H, Abi-Habib R and El-Sibai M: Arginine deprivation: A potential therapeutic for cancer cell metastasis? A review. Cancer Cell Int. 20:1502020. View Article : Google Scholar : PubMed/NCBI | |
Diab S, Yu M and Wang S: CDK7 inhibitors in cancer therapy: The sweet smell of success? J Med Chem. 63:7458–7474. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bechnak L, Khalil C, Kurdi RE, Khnayzer R and Patra D: Curcumin encapsulated colloidal amphiphilic block co-polymeric nanocapsules: Colloidal nanocapsules enhance photodynamic and anticancer activities of curcumin. Photochem Photobiol Sci. 19:1088–1098. 2020. View Article : Google Scholar : PubMed/NCBI | |
Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, Rives S, Del Pozo Carlavilla M, Alonso MEV, Domínguez-Pinilla N, et al: Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 132:11–16. 2020. View Article : Google Scholar : PubMed/NCBI | |
Nassour C, Barton SJ, Nabhani-Gebara S, Saab Y and Barker J: Occurrence of anticancer drugs in the aquatic environment: A systematic review. Environ Sci Pollut Res Int. 27:1339–1347. 2020. View Article : Google Scholar : PubMed/NCBI | |
Mehanna S, Bodman-Smith K, Daher CF and Khnayzer RS: Rapid quantification of ruthenium(ii) polypyridyl anti-cancer drugs using a selective ligand dissociation LC-MS/MS method. Anal Methods. 12:4517–4525. 2020. View Article : Google Scholar : PubMed/NCBI | |
Assi R, Kotecki N and Awada A: Targeting molecular subtypes in solid cancers: Successes and failures. Curr Opin Oncol. 32:488–493. 2020. View Article : Google Scholar : PubMed/NCBI | |
El Baba N, Farran M, Khalil EA, Jaafar L, Fakhoury I and El-Sibai M: The role of Rho GTPases in VEGF signaling in cancer cells. Anal Cell Pathol (Amst). 2020:20972142020.PubMed/NCBI | |
Doumit MAA, Rahi AC, Saab R and Majdalani M: Spirituality among parents of children with cancer in a Middle Eastern country. Eur J Oncol Nurs. 39:21–27. 2019. View Article : Google Scholar : PubMed/NCBI | |
Bar-Sela G, Schultz MJ, Elshamy K, Rassouli M, Ben-Arye E, Doumit M, Gafer N, Albashayreh A, Ghrayeb I, Turker I, et al: Training for awareness of one's own spirituality: A key factor in overcoming barriers to the provision of spiritual care to advanced cancer patients by doctors and nurses. Palliat Support Care. 17:345–352. 2019. View Article : Google Scholar : PubMed/NCBI | |
Al Hageh C, Al Assaad M, El Masri Z, Samaan N, El-Sibai M, Khalil C and Khnayzer RS: A long-lived cuprous bis-phenanthroline complex for the photodynamic therapy of cancer. Dalton Trans. 47:4959–4967. 2018. View Article : Google Scholar : PubMed/NCBI | |
Moghnieh R, Kanafani ZA, Hanna PA, Matar MJ, Mokhbat J, Jradeh M, Yared N, Husni R, Abdallah D, Atoui R, et al: 2016 Lebanese society of infectious diseases and clinical microbiology guidelines on the management of febrile neutropenia in adult cancer patients in the ERA of growing antimicrobial resistance. J Med Liban. 65:63–82. 2017. | |
Doumit MAA and Khoury MN: Facilitating and hindering factors for coping with the experience of having a child with cancer: A Lebanese perspective. J Psychosoc Oncol. 35:346–361. 2017. View Article : Google Scholar : PubMed/NCBI | |
Abd El Razik HA, Mroueh M, Faour WH, Shebaby WN, Daher CF, Ashour HMA and Ragab HM: Synthesis of new pyrazolo[3,4-d]pyrimidine derivatives and evaluation of their anti-inflammatory and anticancer activities. Chem Biol Drug Des. 90:83–96. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liu S, Abboud MI, John T, Mikhailov V, Hvinden I, Walsby-Tickle J, Liu X, Pettinati I, Cadoux-Hudson T, McCullagh JSO and Schofield CJ: Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. Commun Biol. 4:12432021. View Article : Google Scholar : PubMed/NCBI | |
Bar-Sela G, Schultz MJ, Elshamy K, Rassouli M, Ben-Arye E, Doumit M, Gafer N, Albashayreh A, Ghrayeb I, Turker I, et al: Human development index and its association with staff spiritual care provision: A Middle Eastern oncology study. Support Care Cancer. 27:3601–3610. 2019. View Article : Google Scholar : PubMed/NCBI | |
Chemaly R, Diab S, Khazen G and Al-Hajj G: Gastroesophageal cancer after gastric bypass surgeries: A systematic review and meta-analysis. Obes Surg. 32:1300–1311. 2022. View Article : Google Scholar : PubMed/NCBI | |
Assouad E, El Hage S, Safi S, El Kareh A, Mokled E and Salameh P: Kidney cancer trends and risk factors in Lebanon: A 12-year epidemiological study. Cancer Causes Control. 33:303–312. 2022. View Article : Google Scholar : PubMed/NCBI | |
Swayden M, Bekdash A, Fakhoury I, El-Atat O, Borjac-Natour J, El-Sibai M and Abi-Habib RJ: Activation of autophagy following [HuArgI (Co)-PEG5000]-induced arginine deprivation mediates cell death in colon cancer cells. Hum Cell. 34:152–164. 2021. View Article : Google Scholar : PubMed/NCBI | |
Nader R, Tannoury E, Rizk T and Ghanem H: Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: A case report and review of neurological adverse events associated with checkpoint inhibitors. Autops Case Rep. 11:e20212612021. View Article : Google Scholar : PubMed/NCBI | |
El-Mais N, Fakhoury I, Al Haddad M, Nohra S, Abi-Habib R and El-Sibai M: Human recombinant arginase I [HuArgI(Co)-PEG5000]-induced arginine depletion inhibits pancreatic cancer cell migration and invasion through autophagy. Pancreas. 50:1187–1194. 2021. View Article : Google Scholar : PubMed/NCBI | |
Khater AR and Abou-Antoun T: Mesenchymal epithelial transition factor signaling in pediatric nervous system tumors: Implications for malignancy and cancer stem cell enrichment. Front Cell Dev Biol. 9:6541032021. View Article : Google Scholar : PubMed/NCBI | |
Atallah D, Arab W, Dagher B, Khalil N, El Rawadi E, Atallah B, Ghaname W, El Kassis N, Chahine G and Moubarak M: Predictive factors of lymph node metastasis and pattern of repartition in patients with epithelial ovarian cancer. Future Oncol. 17:5093–5101. 2021. View Article : Google Scholar : PubMed/NCBI | |
El-Chami D, Al-Haddad M, Abi-Habib R and El-Sibai M: Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases. Oncol Lett. 21:1632021. View Article : Google Scholar : PubMed/NCBI | |
Hilal L, Hakim A, El-Chediak A, Temraz S, Mukherji D, El-Husseini Z and Shamseddine A: Rectal cancer in patients younger than 40: Tumor characteristics and comparative survival based on a single institution. Current Cancer Therapy Reviews. 17:244–250. 2021. View Article : Google Scholar | |
Jaafar L, Fakhoury I, Saab S, El-Hajjar L, Abou-Kheir W and El-Sibai M: StarD13 differentially regulates migration and invasion in prostate cancer cells. Hum Cell. 34:607–623. 2021. View Article : Google Scholar : PubMed/NCBI | |
Fayad C, Audi H, Khnayzer RS and Daher CF: The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells. J Biol Inorg Chem. 26:43–55. 2021. View Article : Google Scholar : PubMed/NCBI | |
Khalil N and Abi-Habib RJ: [HuArgI (co)-PEG5000]-induced arginine deprivation leads to autophagy dependent cell death in pancreatic cancer cells. Invest New Drugs. 38:1236–1246. 2020. View Article : Google Scholar : PubMed/NCBI | |
Idriss M, Hodroj MH, Fakhoury R and Rizk S: Beta-tocotrienol exhibits more cytotoxic effects than gamma-tocotrienol on breast cancer cells by promoting apoptosis via a P53-independent PI3-kinase dependent pathway. Biomolecules. 10:5772020. View Article : Google Scholar : PubMed/NCBI | |
Nasreddine G, El-Sibai M and Abi-Habib RJ: Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian cancer cells is autophagy dependent. Invest New Drugs. 38:10–19. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bahmad HF, Elajami MK, El Zarif T, Bou-Gharios J, Abou-Antoun T and Abou-Kheir W: Drug repurposing towards targeting cancer stem cells in pediatric brain tumors. Cancer Metastasis Rev. 39:127–148. 2020. View Article : Google Scholar : PubMed/NCBI | |
El Joumaa MM, Taleb RI, Rizk S and Borjac JM: Protective effect of Matricaria chamomilla extract against 1,2-dimethylhydrazine-induced colorectal cancer in mice. J Complement Integr Med. 17:2020. View Article : Google Scholar : PubMed/NCBI | |
Tannous S, Haykal T, Dhaini J, Hodroj MH and Rizk S: The anti-cancer effect of flaxseed lignan derivatives on different acute myeloid leukemia cancer cells. Biomed Pharmacother. 132:1108842020. View Article : Google Scholar : PubMed/NCBI | |
Younes M, Ammoury C, Haykal T, Nasr L, Sarkis R and Rizk S: The selective anti-proliferative and pro-apoptotic effect of A. Cherimola on MDA-MB-231 breast cancer cell line. BMC Complement Med Ther. 20:3432020. View Article : Google Scholar : PubMed/NCBI | |
Ghali RM, Mahjoub S, Zaied S, Bhiri H, Bahia W, Mahjoub T and Almawi WV: Association of genetic variants in NF-kB with susceptibility to breast cancer: A case control study. Pathol Oncol Res. 25:1395–1400. 2019. View Article : Google Scholar : PubMed/NCBI | |
Bahmad HF, Chamaa F, Assi S, Chalhoub RM, Abou-Antoun T and Abou-Kheir W: Cancer stem cells in neuroblastoma: Expanding the therapeutic frontier. Front Mol Neurosci. 12:1312019. View Article : Google Scholar : PubMed/NCBI | |
Al-Koussa H, Al-Haddad M, Abi-Habib R and El-Sibai M: Human recombinant arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits colorectal cancer cell migration and invasion. Int J Mol Sci. 20:60182019. View Article : Google Scholar : PubMed/NCBI | |
Henaine AM, Chahine G, Massoud M, Salameh P, Awada S, Lahoud N, Elias E, Salem M, Ballout S, Hartmann D, et al: Management of patients with metastatic colorectal cancer in Lebanese hospitals and associated direct cost: A multicentre cohort study. East Mediterr Health J. 25:481–494. 2019. View Article : Google Scholar : PubMed/NCBI | |
Cianci S, Rumolo V, Rosati A, Scaletta G, Alletti SG, Cerentini TM, Sleiman Z, Lordelo P, Angerame D, Garganese G, et al: Sarcopenia in ovarian cancer patients, oncologic outcomes revealing the importance of clinical nutrition: Review of literature. Curr Pharm Des. 25:2480–2490. 2019. View Article : Google Scholar : PubMed/NCBI | |
Abou Najem S, Khawaja G, Hodroj MH and Rizk S: Synergistic effect of epigenetic inhibitors decitabine and suberoylanilide hydroxamic acid on colorectal cancer in vitro. Curr Mol Pharmacol. 12:281–300. 2019. View Article : Google Scholar : PubMed/NCBI | |
El-Amm J and Aragon-Ching JB: The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 13:11795549198339272019. View Article : Google Scholar : PubMed/NCBI | |
Hoter A, Rizk S and Naim HY: The multiple roles and therapeutic potential of molecular chaperones in prostate cancer. Cancers (Basel). 11:11942019. View Article : Google Scholar : PubMed/NCBI | |
Al Saud N, Jabbour S, Kechichian E, Aderian SS, Boccara D, Nasr M, El Hachem L and Mimoun M: A systematic review of zosteriform rash in breast cancer patients: An objective proof of flap reinnervation and a management algorithm. Ann Plast Surg. 81:456–461. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bedoui SA, Barbirou M, Stayoussef M, Dallel M, Mokrani A, Makni L, Mezlini A, Bouhaouala B, Yacoubi-Loueslati B and Almawi WY: Association of interleukin-17A polymorphisms with the risk of colorectal cancer: A case-control study. Cytokine. 110:18–23. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ghali RM, Al-Mutawa MA, Al-Ansari AK, Zaied S, Bhiri H, Mahjoub T and Almawi WY: Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features: A case-control study. Gene. 651:194–199. 2018. View Article : Google Scholar : PubMed/NCBI | |
Al Hassan M, Fakhoury I, El Masri Z, Ghazale N, Dennaoui R, El Atat O, Kanaan A and El-Sibai M: Metformin treatment inhibits motility and invasion of glioblastoma cancer cells. Anal Cell Pathol (Amst). 2018:59174702018.PubMed/NCBI | |
Nader R, El Amm J and Aragon-Ching JB: Role of chemotherapy in prostate cancer. Asian J Androl. 20:221–229. 2018. View Article : Google Scholar : PubMed/NCBI | |
Daaboul HE, Daher CF, Bodman-Smith K, Taleb RI, Shebaby WN, Boulos J, Dagher C, Mroueh MA and El-Sibai M: Antitumor activity of β-2-himachalen-6-ol in colon cancer is mediated through its inhibition of the PI3K and MAPK pathways. Chem Biol Interact. 275:162–170. 2017. View Article : Google Scholar : PubMed/NCBI | |
Abou-Antoun TJ, Hale JS, Lathia JD and Dombrowski SM: Brain cancer stem cells in adults and children: Cell biology and therapeutic implications. Neurotherapeutics. 14:372–384. 2017. View Article : Google Scholar : PubMed/NCBI | |
Najar M, Fayyad-Kazan H, Faour WH, Badran B, Journe F and Lagneaux L: Breast cancer cells and bone marrow mesenchymal stromal cells: A regulated modulation of the breast tumor in the context of immune response. Inflamm Res. 66:129–139. 2017. View Article : Google Scholar : PubMed/NCBI | |
Salem C, Atallah D, Safi J, Chahine G, Haddad A, El Kassis N, Maalouly LM, Moubarak M, Dib M and Ghossain M: Breast density and breast cancer incidence in the lebanese population: results from a retrospective multicenter study. Biomed Res Int. 2017:75949532017. View Article : Google Scholar : PubMed/NCBI | |
El-Amm J, Nassabein R and Aragon-Ching JB: Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: Current perspectives. Cancer Manag Res. 9:299–306. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shebaby WN, Mroueh MA, Boukamp P, Taleb RI, Bodman-Smith K, El-Sibai M and Daher CF: Wild carrot pentane-based fractions suppress proliferation of human HaCaT keratinocytes and protect against chemically-induced skin cancer. BMC Complement Altern Med. 17:362017. View Article : Google Scholar : PubMed/NCBI | |
Centre for Reviews & Dissemination. Systematic Reviews, . CRD's Guidance for Undertaking Reviews in Healthcare. University of York; York, UK: pp. 78–108. 2008 | |
Dang D, Dearholt S, Bissett K, Ascenzi J and Whalen M: Johns Hopkins evidence-based practice for nurses and healthcare professionals: Model and guidelines. 4th ed. Sigma Theta Tau International; 2022 | |
Cekanova M and Rathore K: Animal models and therapeutic molecular targets of cancer: Utility and limitations. Drug Des Devel Ther. 8:1911–1921. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ferreira D, Adega F and Chaves R: The importance of cancer cell lines as in vitro models in cancer methylome analysis and anticancer drugs testing. InTech; 2013, View Article : Google Scholar | |
Godskesen T, Hansson MG, Nygren P, Nordin K and Kihlbom U: Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials. Eur J Cancer Care (Engl). 24:133–141. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hanna CR, Boyd KA and Jones RJ: Evaluating cancer research impact: Lessons and examples from existing reviews on approaches to research impact assessment. Health Res Policy Sys. 19:362021. View Article : Google Scholar : PubMed/NCBI | |
Boutros P and Fakih A: Drivers of Research Outcomes in Developing Countries: The Case of Lebanon. Economie. 10:582022. View Article : Google Scholar | |
LAU website, . https://dira.lau.edu.lb/images/Factbook%202017-2018%20-General%20Information.pdfMay 30–2023 | |
Haffar D: LAU strategy yields a marked rise in research output. 2022. https://news.lau.edu.lb/2022/lau-strategy-yields-a-marked-rise-in-research-output.php#:~:text=In%20terms%20of%20quality%2C%20LAU,over%20the%20past%2025%20yearsMay 30–2022 | |
Mattiuzzi C and Lippi G: Current cancer epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI | |
Cancer Research UK: Current Clinical Trial Research. https://www.cancerresearchuk.org/ourresearch-by-cancer-topic/our-clinical-trialresearch/current-clinical-trial-researchMay 30–2022 | |
Dabin K: Our mutual fiends: Cancer Research in a time of COVID-19. Interface Focus. 11:202100522021. View Article : Google Scholar : PubMed/NCBI | |
Janowitz T and Tuveson DA: The era of COVID-19 and the rise of science collectivism in cancer research. Cancer Discov. 10:913–915. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bizri AR, Khachfe HH, Fares MY and Musharrafieh U: COVID-19 pandemic: An insult over injury for Lebanon. J Community Health. 46:487–493. 2021. View Article : Google Scholar : PubMed/NCBI | |
Bouri E, Cepni O, Gabauer D and Gupta R: Return connectedness across asset classes around the COVID-19 outbreak. Int Rev Fin Anal. 73:1016462020. View Article : Google Scholar | |
Fares MY, Salhab HA, Khachfe HH and Khachfe HM: Breast cancer epidemiology among Lebanese women: An 11-year analysis. Medicina (Kaunas). 55:4632019. View Article : Google Scholar : PubMed/NCBI |